This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Org 25935
Description: Org 25935 is believed specifically to act as a glycine uptake (GlyT-1) inhibitor to enhance NMDA receptor function mediated through increased brain levels of glycine.
Deal Structure: Org 25935 was originally developed by N.V. Organon.
In November 2007, Schering-Plough completed the acquisition of Organon BioSciences N.V. Schering-Plough's agreement to acquire Organon BioSciences was announced on March 12, 2007. Schering-Plough acquired Organon BioSciences from Akzo Nobel N.V. for approximately euro 11 billion in cash.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. The acquisition was completed in November 2009.
SCH 900435 News
Additional information available to subscribers only: